TY - JOUR
T1 - Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure
AU - Kemp-Harper, Barbara K.
AU - Horowitz, John D
AU - Ritchie, Rebecca H.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Heart failure (HF) is a major cause of hospital admission in the Western world, yet there remains a paucity of effective pharmacological management options. With the recent development of synthetic, next-generation nitroxyl (HNO) donors and their progress into clinical trials, it is timely to now provide an update on the therapeutic potential of HNO donors in the management of acute decompensated heart failure. In this article, we summarize current understanding of the pharmacology of HNO (in comparison with its redox sibling, nitric oxide), its spectrum of cardioprotective actions, and efforts to translate these into the clinic. Future research directions for this exciting new class of HF drugs are also considered.
AB - Heart failure (HF) is a major cause of hospital admission in the Western world, yet there remains a paucity of effective pharmacological management options. With the recent development of synthetic, next-generation nitroxyl (HNO) donors and their progress into clinical trials, it is timely to now provide an update on the therapeutic potential of HNO donors in the management of acute decompensated heart failure. In this article, we summarize current understanding of the pharmacology of HNO (in comparison with its redox sibling, nitric oxide), its spectrum of cardioprotective actions, and efforts to translate these into the clinic. Future research directions for this exciting new class of HF drugs are also considered.
UR - https://www.scopus.com/pages/publications/84983781347
U2 - 10.1007/s40265-016-0631-y
DO - 10.1007/s40265-016-0631-y
M3 - Article
C2 - 27566478
AN - SCOPUS:84983781347
SN - 0012-6667
VL - 76
SP - 1337
EP - 1348
JO - Drugs
JF - Drugs
IS - 14
ER -